Huntington's disease (HD) is a dominant inherited neurodegenerative disorder that affects 1 in 10,000 in the U.S. Knowledge of the HD mutation, a CAG expansion that extends a run of glutamines in huntingtin, has spurred elucidation of the HD pathogenic mechanism and related polyglutamine disorders. Mutant huntingtin's HD pathogenic-trigger comprises two components: a novel toxicity property of polyglutamine conferred on the amino terminus and another intrinsic feature of the 350 kDa protein that renders striatal neurons especially vulnerable. By inserting HD CAG repeats into the mouse's HD gene (Hdh), we have uncovered abnormal conformational properties of full-length mutant huntingtin that precede truncated-aggregate and neuronal atrophy. The striatal neuron specificity, dominance and glutamine progressively implicate these events early in the human disease. We have demonstrated by Hdh inactivation and studies in striatal cells that huntingtin displays alternate conformations (consistent with distinct complexes) that associate with different sets of nuclear RNA and cytoplasmic membrane organelles that require its function. We have demonstrated regulation of huntingtin levels that implicates it in a diversity of physiologic adoptions to altered cellular homeostasis. In the renewal period, we aim to pursue the delineation of both components of HD pathogenesis. To investigate the specificity element, we will more precisely define huntingtin's normal function, placing it within the RNAprotein energy pathway and delineating regulatory features important to the metabolism of striatal neurons. To define the polyglutamine component, we will assess modifications and interactions unique to mutant huntingtin, test factors that modify its abnormal behaviors and assess the contribution of physiologic regulation. Our long-term goal continues to be a detailed understanding of the initial steps of the HD pathogenic cascade in order to be able to target specific processes for the development of effective therapies for this tragic disorder.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS032765-09
Application #
6539784
Study Section
Mammalian Genetics Study Section (MGN)
Program Officer
Oliver, Eugene J
Project Start
1994-05-01
Project End
2005-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
9
Fiscal Year
2002
Total Cost
$396,000
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Labadorf, Adam; Hoss, Andrew G; Lagomarsino, Valentina et al. (2015) RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression. PLoS One 10:e0143563
Carroll, Jeffrey B; Deik, Amy; Fossale, Elisa et al. (2015) HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation. PLoS One 10:e0134465
Ramos, Eliana Marisa; Gillis, Tammy; Mysore, Jayalakshmi S et al. (2015) Haplotype analysis of the 4p16.3 region in Portuguese families with Huntington's disease. Am J Med Genet B Neuropsychiatr Genet 168B:135-43
Ramos, Eliana Marisa; Kovalenko, Marina; Guide, Jolene R et al. (2015) Chromosome substitution strain assessment of a Huntington's disease modifier locus. Mamm Genome 26:119-30
Biagioli, Marta; Ferrari, Francesco; Mendenhall, Eric M et al. (2015) Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. Hum Mol Genet 24:2442-57
Ramos, Eliana Marisa; Gillis, Tammy; Mysore, Jayalakshmi S et al. (2015) Prevalence of Huntington's disease gene CAG trinucleotide repeat alleles in patients with bipolar disorder. Bipolar Disord 17:403-8
Galkina, Ekaterina I; Shin, Aram; Coser, Kathryn R et al. (2014) HD CAGnome: a search tool for huntingtin CAG repeat length-correlated genes. PLoS One 9:e95556
Hoss, Andrew G; Kartha, Vinay K; Dong, Xianjun et al. (2014) MicroRNAs located in the Hox gene clusters are implicated in huntington's disease pathogenesis. PLoS Genet 10:e1004188
Zhang, Bin; Gaiteri, Chris; Bodea, Liviu-Gabriel et al. (2013) Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153:707-20
Ramos, Eliana Marisa; Latourelle, Jeanne C; Gillis, Tammy et al. (2013) Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics 14:173-9

Showing the most recent 10 out of 79 publications